

Year-end report 2025



Surgical Science is a global leader in evidence-based medical simulation. The company's virtual reality simulators and customized training solutions enable surgeons and healthcare professionals to practice and improve their skills outside the operating room - enhancing patient safety and clinical outcomes. Also, Surgical Science partners with medical technology and robotics companies to integrate tailor-made simulation technology into their devices, helping them accelerate innovation and gain a competitive edge.

Surgical Science has approximately 310 employees. The company is headquartered in Gothenburg, Sweden, and has operations in Tel Aviv, Israel; Stockholm, Sweden; Cleveland, US; and Cardiff, UK. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market, Stockholm, Sweden. Certified Adviser is DNB Carnegie Investment Bank AB.

Profitability in line with financial targets

Fourth quarter 2025 (Oct – Dec)

- Net sales amounted to SEK 268.9 (251.5) million, an increase of 7 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales increased by 15 percent.
- Sales of SEK 14.2 million from Intelligent Ultrasound are included in the figures. For comparable units, sales increased by 1 percent.
- License revenue amounted to SEK 92.3 (76.4) million and accounted for 34 (30) percent of net sales.
- The gross margin was 66 (68) percent.
- Operating profit amounted to SEK 40.1 (39.1) million. Currency effects of SEK -7.5 (-5.3) million are included in the line item Other operating income and costs.
- Net profit amounted to SEK 33.3 (36.3) million, corresponding to earnings per share of SEK 0.65 (0.71).
- Cash flow from operating activities amounted to SEK 72.9 (56.7) million. As at December 31, 2025, cash and cash equivalents amounted to SEK 616.4 (968.2) million.
- On November 25, it was announced that the memorandum of understanding signed on January 15 with the company's largest customer, Intuitive, did not materialize into a signed agreement. This means that, as of January 1, 2026, the parties revert to the existing agreement. Surgical Science estimates that this will have a negative impact on the company's license revenues in the range of SEK 60-90 million for 2026, compared to 2025.
- On December 8, Surgical Science announced new financial targets. Growth shall amount to 10-15 percent annually with an adjusted EBIT of at least 15 percent. Profitability and some sales growth is expected for 2026, although not in line with the targets. The targets are expected to be met in 2027. At the same time, the intention to begin the process of switching to the Nasdaq Main Market was announced.

Full year 2025

- Net sales amounted to SEK 992.3 (884.1) million, an increase of 12 percent compared with the preceding year. Calculated in local currencies, sales increased by 19 percent.
- For comparable units, sales increased by 4 percent.
- License revenue amounted to SEK 300.6 (271.7) million and accounted for 30 (31) percent of net sales.
- The gross margin was 66 (68) percent.
- Operating profit amounted to SEK 68.9 (144.3) million. Profit includes SEK 22.6 million in acquisition costs and SEK 5.3 million in restructuring costs, which are attributable to the acquisition of Intelligent Ultrasound. Currency effects of SEK -37.7 (0.1) million are included in the line item Other operating income and costs.
- Net profit amounted to SEK 66.8 (131.6) million, corresponding to earnings per share of SEK 1.31 (2.58).
- Cash flow from operating activities amounted to SEK 79.8 (137.2) million.
- Intelligent Ultrasound, which operates in the field of ultrasound simulation, was acquired in February. The acquisition date was February 18.

Key figures

	January – December		October – December	
	2025	2024	2025	2024
Net sales, SEK million	992.3	884.1	268.9	251.5
Operating profit (EBIT), SEK million	68.9	144.3	40.1	39.1
Operating profit (EBIT) excluding acquisition and restructuring costs, SEK million	99.5	144.3	42.8	39.1
Adjusted EBIT, SEK million	91.8	168.7	45.7	45.3
Adjusted EBIT margin, %	9.3	19.1	17.0	18.0
Adjusted EBIT margin, excluding acquisition and restructuring costs, %	12.3	19.1	18.0	18.0
Profit after financial items, SEK million	100.1	158.1	42.5	39.4
Net profit, SEK million	66.8	131.6	33.3	36.3
No. employees at end of period	313	274	313	274
Equity/assets ratio, %	91.1	88.1	91.1	88.1
Earnings per share, SEK	1.31	2.58	0.65	0.71
Equity per share, SEK	83.74	94.63	83.74	94.63
Share price on the balance sheet date, SEK	32.50	155.90	32.50	155.90
Market value on balance sheet date, SEK million	1,658.4	7,955.0	1,658.4	7,955.0

For definitions, see page 23.

A message from the CEO

Like Q3, Q4 was a clear step in the right direction for Surgical Science. Sales amounted to SEK 269 million and grew by 15 percent adjusted for currency effects. License revenues were the highest ever reported, amounting to SEK 92 million, an increase of 21 percent. Adjusted EBIT amounted to SEK 46 million (17%) and cash flow from operating activities was SEK 73 million.

On December 8, 2025, Surgical Science presented new financial targets of annual sales growth of 10-15 percent with profitability (adjusted EBIT) of more than 15 percent. It is gratifying to see that we are now delivering fourth-quarter results in line with these targets.

On the same day that the new financial targets were announced, we also held a Capital Markets Day where our new strategy was presented. This strategy broadens the prioritized customer segments to five, all with clearly defined goals. During the quarter, we took clear steps toward delivering on these strategic goals and saw a generally high level of activity, in respect of both our customers and internally.

Educational Products

Performance in Educational Products was mixed, with growth of 4 percent. North and South America showed strong growth of 43 percent with a good distribution between countries. We are seeing a clear recovery in the region compared with previous quarters and are cautiously optimistic about the future. Asia, on the other hand, saw sales decline by 21 percent, driven by a continued challenging market situation in China with generally lower activity and demand.

One of our strategic goals is to increase profitability in all segments outside Robotics. For our high-volume products, we are now beginning to see the impact of this strategic initiative. During Q4 2025, our average sales prices increased by around 9 percent compared with Q4 2024 at fixed exchange rates, without us experiencing any significant effect on volumes. The impact is felt most in direct sales. Indirect channels usually show a delay, and we expect further positive price effects to be seen in 2026.

During the quarter, our new PartnerPath distributor program was introduced on a broad scale. This program aims to improve cooperation, sales, and efficiency between us and our partners, which in turn will also contribute to increased profitability.



Ultrasound

The Ultrasound segment experienced a very high level of activity, in respect of both hospitals and industrial customers. Although ultrasound sales increased by 48 percent compared to Q4 2024, they did not meet our growth expectations as pro forma sales, including the acquisition of Intelligent Ultrasound, declined.

Three new simulation modules were launched during Q4 and in January. One of these is targeted towards the diagnosis of endometriosis, which is a major health problem affecting one in ten women. The module supports one of our focus areas, women's health, an area that is neglected in healthcare and where we have identified that our unique products and solutions can create significant value and contribute to earlier diagnosis.

During Q1, the first products based on the joint technology platform from Surgical Science and Intelligent Ultrasound will be launched. We still have a lot of work to do to realize the full synergies from the acquisition of Intelligent Ultrasound.

Industry/OEM

Robotics

The Robotics segment had a strong quarter. License revenue grew by 21 percent to SEK 92 million, which was an all-time high for the company. We saw strong license revenues from

Digital offerings are becoming increasingly important for robotics companies, and Surgical Science is playing a central role in the development of these offerings.

our largest customer, Intuitive, as well as several other players in the US and China. These other players are now beginning to install robots in significant numbers, which is in turn driving our license revenues.

The collaboration with our largest customer, Intuitive, continued during the quarter, and in January 2026, Intuitive announced that its system had been used on more than 20 million patients to date. This, together with the 18 percent growth in procedures during the quarter, is clear evidence of the strong demand and broad adoption of robotic surgery. Both Intuitive and Surgical Science agree on the critical role simulation plays in training robotic surgeons. Digital offerings are becoming increasingly important for robotics companies, and Surgical Science is playing a central role in the development of these offerings.

During the quarter, our customer Johnson & Johnson applied for a De Novo classification in order to market its Ottava robot for gastrointestinal procedures. Another customer, Medtronic, received FDA approval for the use of its Hugo robot in urological procedures in the US. Two other Surgical Science customers – Distalmotion (Switzerland) and Ronovo (China) – announced major investments from Johnson & Johnson with a view to accelerating product development in their respective businesses.

There are now several hundred robot models that are either actively being sold or are about to hit the market. Surgical Science is developing simulation solutions for most of the 20 largest robotics companies. We feel very confident in the value and uniqueness of our offering in robotic surgery. We see opportunities for deeper integration into our customers' digital offerings and creating value for many years to come, in line with our new strategy.

Surgical Science is currently making significant progress in its product offering for robotics, and we are constantly improving our core technology. The introduction of our latest simulator, RobotiX Express, has been successful, and sales and deliveries have started to pick up speed. Fourteen simulation exercises have been launched on the simulator so far, and the portfolio will be expanded on an ongoing basis. This product has the potential to contribute significantly to our sales in the coming years.

At the International Meeting on Simulation in Healthcare

(IMSH) in San Antonio in January, we showcased our AI-enabled products for the first time ever. In these, AI is helping to analyze the instrument handling of laparoscopic surgeons and then recommends steps or skills for the surgeon to practice and improve. At the same time, within our core offering of real-time simulation of surgical procedures, we see major limitations in the power and scalability of AI to handle and calculate models that could generate the complex real-time surgical simulation that our customers require.

Surgical Science's simulation technologies will continue to be the ultimate solution for high-quality real-time surgical simulation for the foreseeable future. We are testing AI in parallel in the areas where it can create value today and are accelerating the pace as the technology matures.

Medical Device Simulation

During Q4, continued progress was also made in strengthening the company's position within the medical device industry, with a focus on endovascular applications. At the end of the year, the pipeline of ongoing development projects was 15 percent larger than at the same point in 2024.

Our development revenue is project-based and may fluctuate between quarters and not fully reflect the underlying level of activity. At the end of 2025, the proportion of repeat customers for development projects exceeded 70 percent, demonstrating that Surgical Science is making progress toward becoming an even more integrated and long-term partner to these customers. During the quarter, several important solutions were delivered to our customers, including in the areas of peripheral artery disease and pulmonary thrombectomy.

At the same time, sales of simulators to medical device companies for product-specific training fell to SEK 21 million compared with a very strong comparative quarter of SEK 43 million. Similar to development revenue, we see that this revenue can vary between quarters based on when our customers place these often large orders.

Costs and results

The gross margin for the quarter was 66 (68) percent. Although the profitability improvement measures introduced throughout 2025 have now started to have a positive impact on earnings, they have not yet achieved their full effect. On the one hand, we have had a currency effect that has had a negative impact in the other direction, and on the other hand,

the sales cycles for our products average between 3 and 6 months, which means that the profit-enhancing effect is delayed by the length of the sales cycle.

During the quarter, the offices in the US were consolidated to create a more efficient structure, which resulted in the closure of the Seattle office. We have also achieved greater savings than planned in the Intelligent Ultrasound integration project. Sales costs fell to SEK 47 (50) million despite an increase in customs duties of just under SEK 3 million.

Adjusted EBIT was in line with our financial targets and amounted to SEK 46 million (17%). Cash flow from operating activities was SEK 73 million.

The strategy and work going forward

Surgical Science's new strategy was presented at the Capital Markets Day in December 2025. The aim is to continue growing the company profitably and establish a market-leading position in our five different market segments, all of which currently have low to very low penetration. We are now pursuing active internal efforts to deliver on the strategy and are seeing progress across all initiatives.


Surgical Science is currently a world leader in medical simulation with a very strong brand. Our position is unique, with market-leading products, strong and effective direct and indirect sales channels, and extensive medical expertise that our

customers rely on for their training and development. Our global reach and support, which ensure reliability and presence, are critical factors for our customers.

2025 has been a challenging year in many ways, particularly in relation to the news surrounding our largest customer, Intuitive, and the development of our share price. At the same time, Surgical Science has made great strides forward in many respects and is now in many ways a significantly stronger company than it was a year ago. Demand for our products is growing steadily, driven by a greater need for training, increased digitalization, and more complex healthcare. I am optimistic about the future, where our solutions will become a central part of health-care training, and our ability to generate profitable growth over time.

I would like to express my sincere gratitude to all our fantastic employees for their tireless commitment and valuable work throughout the year. I would also like to express my sincere gratitude to our customers and shareholders for their trust in Surgical Science.

Gothenburg, February 2026



Tom Englund, CEO

Fourth quarter 2025 (October – December)

Net sales

Net sales for the fourth quarter of the year amounted to SEK 268.9 (251.5) million, an increase of 7 percent compared with the same period in the preceding year. Calculated in local currencies, sales increased by 15 percent.

Of the sales for the quarter, SEK 129.5 (125.0) million consisted of sales within the Educational Products business area and SEK 139.3 (126.5) million within the Industry/OEM business area.

Net sales for Intelligent Ultrasound of SEK 14.2 million (now Surgical Science UK, but Intelligent Ultrasound will still be used in the report) are included in sales for the fourth quarter of 2025 and are recognized exclusively within the Educational Products business area. For comparable units, sales increased by 1 percent.

As of 2025, note 2 on page 20 has been revised and expanded. Sales have been divided by product group, regardless of the business area from which they originate. Sales in

Intelligent Ultrasound are included in their entirety in the ultrasound product group.

Educational Products

Sales in Educational Products increased by 4 percent, but decreased by 8 percent when excluding sales originating from Intelligent Ultrasound. Simulator sales amounted to SEK 109.8 (107.1) million and service revenue to SEK 19.7 (18.0) million.

The Asia region declined by 21 percent compared with the same quarter last year. Sales in China had a weaker quarter, while Japan and the Philippines showed healthy sales. Sales from Intelligent Ultrasound for the region were SEK 0.7 million.

Sales in Europe increased by 4 percent, with France and Poland performing particularly well. The comparative figure includes a major order to Romania. Sales from Intelligent Ultrasound for the region were SEK 5.7 million.

The North and South America region increased by 43 percent compared with the corresponding quarter last year. The increase is attributable to the US, even when excluding sales from Intelligent Ultrasound for the region, amounting to SEK 7.2 million. These sales were exclusively to the US.

The region Other declined by 72 percent compared with a strong comparative quarter that included transactions in Pakistan and Australia, for example. Sales from Intelligent Ultrasound for the region were SEK 0.6 million.

In terms of sales per region, in general these vary markedly between different countries and periods within Educational Products – when a major procurement is completed in one country, it is quite natural for there to be lower sales in that market in subsequent periods. It can therefore be difficult to draw general conclusions from comments for individual countries between periods.

Industry/OEM

Industry/OEM showed an increase of 10 percent.

License revenue for the fourth quarter amounting to SEK 92.3 (76.4) million were the highest ever recorded and represent an increase of 21 percent compared with the same period in the preceding year. Sales accounted for 34 (30) percent of the company's total revenue. Revenues include strong sales to the company's largest customer, Intuitive, both in terms of simulation for da Vinci 5 (dV5) and for older generations, such as da Vinci Xi.

On November 25, Surgical Science announced that the memorandum of understanding signed on January 15 with Intuitive did not materialize into a signed agreement. This means that, as of January 1, 2026, the parties revert to the existing agreement. Surgical Science estimates that this will have a negative impact on the company's license revenues in the range of SEK 60-90 million for 2026, compared to 2025. Intuitive has decided to offer the simulation content from Surgical Science to selected dV5 customers, who represent a minority of the installed base for dV5. However, all dV5 systems will contain a basic skills simulation package developed and owned by Intuitive.


Surgical Science and Intuitive share the view that simulation plays a critical role in robotic surgery training, and the companies continue to work closely together on a roadmap where procedural simulation will become an integral part of the overall digital offering. For other robot systems, such as da Vinci X and Xi, the existing agreement remains in place and the simulation package for these products is offered as an optional feature for all customers, as before.

Robotics customers who have just started selling the products from which Surgical Science earns license revenue buy the licenses in packages, which means that this revenue varies more between quarters. Revenues for the fourth quarter include a larger package order from one of Surgical Science's other robotics customers.


Development revenue, which will generate simulator and license revenue at a later stage, remained strong during the fourth quarter (SEK 21.5 million compared to SEK 4.7 million in the preceding year). These revenues partly include revenue from robot projects, as well as from the adaptation or development of software linked to the sale of simulators, see below. The quarter includes revenues of USD 0.7 million attributable to the order to supply products to a ministry of defense in a Southeast Asian country, which totals approximately SEK 52 million. Revenue of USD 0.7 million is expected to be recognized for the first quarter of 2026. This project will be fully recognized under Industry/OEM, while the EmergeX Mentor (formerly TraumaVR) products sold to hospitals will continue to be recognized under Educational Products.

Sales of simulators to medical device companies for product-specific training amounted to SEK 21.4 million compared with a very strong comparative quarter of SEK 42.5 million. Revenues vary significantly more between quarters than the corresponding sales within Educational Products. These projects have longer lead times and usually include a number of simulators where adaptations for product-specific training of, for example, an OEM company's specific instrument are

Revenue by revenue stream



Revenue by business area



included.

Service revenue for the installed base, which is mainly linked to longer agreements with specific OEM customers where Surgical Science takes care of the shipping and servicing of their simulators (currently primarily in the US), amounted to SEK 4.1 (3.0) million.

Costs and results

The cost of goods sold amounted to SEK 90.6 (81.5) million corresponding to a gross margin of 66 (68) percent. License revenue made up a greater share of total sales than the corresponding period in the preceding year, which has a positive effect on the margin. Currency effects had a negative impact on the margin of approximately 2.3 percentage points. The lower USD exchange rate has less impact on the cost of goods sold than on other cost items, as input goods are primarily purchased in currencies other than USD. Production and associated wage costs are also not in USD. Intelligent Ultrasound has a lower gross margin on its products.

Sales costs amounted to SEK 47.0 (50.0) million, corresponding to 17 (20) percent of sales. Starting in the second quarter, additional costs were incurred for customs duties on simulators distributed from production units outside the US. These amounted to approximately SEK 2.6 million during the quarter. The cost has been passed on to customers. During the quarter, the reductions in the sales force following the acquisition of Intelligent Ultrasound achieved their full effect. Lower costs of a more non-recurring nature were due to lower agency costs, which are attributable to sales in certain countries.

Administration costs amounted to SEK 24.5 (22.3) million corresponding to 9 (9) percent of sales. The quarter saw higher consultancy costs related to the administration of internal dividends, as well as higher accounting and recruitment costs. Additional costs attributable to the company's Capital Markets Day are also included.


Research and development costs for the year amounted to SEK 59.8 (51.7) million, corresponding to 22 (21) percent of sales. Of the development costs, SEK 9.5 (10.2) million has been capitalized as intangible assets. The costs on this line also vary depending on how much development revenue there is for the quarter, as salaries for the portion of development department staff who have worked on projects that generated development revenue are transferred to the cost of goods sold. The quarter includes restructuring costs of SEK 2.7 million related to the termination of development personnel in Seattle.

During the fourth quarter, the US operations were restructured, resulting in the closure of the Seattle office and its consolidation to Cleveland. This office will be the company's hub for all commercial activities, services, and customer interaction. In connection with the restructuring, the employment of development staff in Seattle was terminated. A few other roles, where people work remotely, remain. The lease for the Seattle office runs until October 2027.


Upon the acquisition of Intelligent Ultrasound, Surgical Science stated that the company estimated that rationalizations and cost savings equivalent to between GBP 1.5 and 2 million on an annual basis would be possible after the acquisition. On an annual basis, cost savings of approximately GBP 2.5 million in relation to the cost structure that existed in the company at the time of the takeover have been implemented, mainly in the form of reduced costs related to the company's previous stock market listing and staff reductions, mainly within sales. These cost savings achieved their full impact in the fourth quarter and amounted to just over SEK 8 million.

Outstanding warrants programs have in the quarter had an effect on other operating costs in the amount of SEK -0.2 (1.5) million. For further information, see Note 4 on pages 20 and 21. The amount represents a calculation of IFRS 2 regarding the parts of the programs attributable to Israel, the US, and the UK and is allocated across each program's term.

Adjusted EBIT*



Net cash/Accounts receivable



* Excluding acquisition and restructuring costs related to IU in Q1 and Q3 2025 and Seattle in Q4 2025.

Other items under "Other operating income and operating costs" are mainly attributable to the revaluation of operating assets and operating liabilities in a foreign currency. Currency effects had an impact on profits in the amount of SEK -7.5 (-5.3) million.


Operating profit for the fourth quarter amounted to SEK 40.1 (39.1) million, corresponding to an operating margin of 15 (16) percent. The operating profit for Intelligent Ultrasound was SEK -4.8 million (GBP -0.4 million).

Depreciation and amortization burdened profit by SEK 23.9 (16.3) million in total. Depreciation and amortization burdened the cost of goods sold by SEK 0.7 (0.5) million, sales costs by SEK 7.2 (4.9) million, administration costs by SEK 7.8 (5.8) million, and research and development costs by SEK 8.2 (5.1) million. Sales costs include amortization of SEK 3.7 (4.0) million on those parts of the company's acquisitions that are classified as customer contracts, while research and development costs include amortization of SEK 1.9 (2.1) million on those parts of the company's acquisitions that are classified as technology. Depreciation attributable to the application of IFRS 16 amounts to SEK 6.3 (4.9) million, this being included in its entirety under administration costs.

Adjusted EBIT amounted to SEK 45.7 (45.3) million, corresponding to a margin of 17 (18) percent.

EBITDA amounted to SEK 64.1 (55.5) million, corresponding to a margin of 24 (22) percent.

Costs/margin as a percentage of sales



Surgical Science has no loan financing, net financial items for the quarter amounted to SEK 2.4 (0.3) million and mainly consisted of interest income/costs on bank deposits of SEK 2.9 (3.7) million, the revaluation of internal loan liabilities to subsidiaries of SEK -0.8 (-3.9) million, and the effect of IFRS 16 of SEK 0.3 (0.8) million.

Net profit for the quarter amounted to SEK 33.3 (36.3) million. The tax expense for the quarter of SEK 9.2 (3.2) million consists of estimated tax on profit for the period and a change in deferred tax assets. The effective tax rate is lower than in the

previous quarter. The change is due to taxes attributable to the 2024 fiscal year in the US being settled during the quarter.

Cash flow

During the period October to December 2025, cash flow from operating activities amounted to SEK 72.9 million, compared with SEK 56.7 million for the corresponding period in 2024. Cash flow from changes in working capital amounted to SEK -3.0 (-2.2) million. Inventory remained largely unchanged. Accounts receivable decreased while accrued income increased. Short-term liabilities also increased.

Cash flow from investing activities amounted to SEK -15.1 (-12.1) million, mainly comprising investments in development related to the company's software. During the quarter, SEK 3.2 million was invested in the company's ongoing construction of new production facilities in Tel Aviv, which are expected to be commissioned in the second quarter of 2026.

Cash flow from financing activities amounted to SEK -25.7 (240.0) million, where SEK -27.5 (4.1) million was attributable to changes in lease liabilities in accordance with IFRS 16. In connection with the offer to acquire Intelligent Ultrasound in December 2024, a short-term loan of GBP 17 million was taken out, which increased cash flow from financing activities in the comparative period by SEK 235.4 million.

The exchange rate difference in cash and cash equivalents amounted to SEK -13.1 (17.2) million. Net cash flow for the quarter, including currency effects in liquid assets, was SEK 19.0 (301.8) million.

Full year 2025

Net sales

Net sales for 2025 amounted to SEK 992.3 (884.1) million, an increase of 12 percent compared with the preceding year. Calculated in local currencies, sales increased by 19 percent.

Net sales for Intelligent Ultrasound are included in sales for the period from February 18, 2025, amounting to SEK 75.3 million. For the period January 1 to February 17, Intelligent Ultrasound's sales amounted to SEK 4.9 million, meaning that total sales for 2025 amounted to SEK 80.2 (115.8) million. All sales are attributable to the Educational Products business area and the ultrasound product group. For comparable units, sales increased by 4 percent.

Of the sales for the year, SEK 501.5 (442.5) million consisted of sales within the Educational Products business area, an increase of 13 percent. Sales within the Industry/OEM business area amounted to SEK 490.8 (441.6) million, an increase of 11 percent.

For revenues by segment, see Note 2 on page 20. License revenue increased by 11 percent and amounted to SEK 300.6 (271.7) million, 30 (31) percent of the company's total revenues.

Net sales rolling 12 months



Costs and results

The cost of goods sold amounted to SEK 334.7 (286.2) million corresponding to a gross margin of 66 (68) percent. License revenue made up a slightly lower share of total sales than in the preceding year, which had a negative effect on the margin. Currency effects and the fact that Intelligent Ultrasound has a lower gross margin on its products also had a negative impact on the margin. Price increases have had a positive impact on margins.

Sales costs amounted to SEK 214.4 (175.3) million, corresponding to 22 (20) percent of sales. SEK 5.3 million relates to restructuring costs attributable to the acquisition of Intelligent Ultrasound. Excluding these costs, sales costs amounted to SEK 209.1 million, corresponding to 21 percent of sales.

Administration costs amounted to SEK 112.2 (77.1) million corresponding to 11 (9) percent of sales. These costs include Surgical Science's acquisition costs of SEK 22.6 million related to Intelligent Ultrasound. These costs consisted mainly of legal advice in the complicated process of acquiring a listed company in the UK through a court process. Excluding these costs, administration costs amounted to SEK 89.6 million, corresponding to 9 percent of sales.

Research and development costs amounted to SEK 222.1 (196.1) million, corresponding to 22 (22) percent of sales. During the year, development costs of SEK 36.8 (38.3) million were capitalized as an intangible asset. The fourth quarter includes restructuring costs of SEK 2.7 million related to the termination of development personnel in Seattle.

Outstanding warrants programs were charged against other operating costs for 2025 in the amount of SEK 7.5 (7.9) million. Other items under "Other operating income and operating costs" are mainly attributable to the revaluation of operating assets and operating liabilities in a foreign currency,

amounting to SEK -37.7 (0.1) million. 2025 also includes non-recurring income (GBP 0.4 million or SEK 5.8 million) in Intelligent Ultrasound, for a replacement program of older products. The cost of these is found on the same line (GBP -0.2 million or SEK -2.9 million).

Operating profit for 2025 amounted to SEK 68.9 (144.3) million, corresponding to an operating margin of 7 (16) percent. Adjusted for acquisition and restructuring costs, operating profit amounted to SEK 99.5 million, corresponding to a margin of 10 percent. Operating result consolidated for Intelligent Ultrasound is GBP -1.9 million or SEK -23.7 million. The company's total operating result for the year, including result before the acquisition on February 18, was GBP -4.1 million or SEK -53.4 million. Operating result for the period before the acquisition includes Intelligent Ultrasound's costs for advisors in connection with the acquisition, amounting to GBP 1.2 million or SEK 16.4 million.

Operating profit, with revenues and costs restated using the previous year's exchange rates and adjusted for acquisition costs and restructuring costs related to Intelligent Ultrasound and Seattle, amounted to approximately SEK 177 million, or 17 percent.

With regard to the surplus value in the group attributable to the acquisition of Intelligent Ultrasound, amounting to SEK 16.6 million, no allocation has been made to amortizable assets and, consequently, no amortization is made on such surplus values.

Depreciation and amortization burdened profit by SEK 83.4 (60.5) million in total. Depreciation and amortization burdened the cost of goods sold by SEK 2.6 (2.0) million, sales costs by SEK 21.2 (19.1) million, administration costs by SEK 28.9 (19.7) million, and research and development costs by SEK 30.7 (19.7) million. Sales costs include amortization of SEK 15.2 (16.0) million on those parts of the company's acquisitions that are classified as customer contracts, while research and development costs include amortization of SEK 7.7 (8.3) million on those parts of the company's acquisitions that are classified as technology. Depreciation attributable to the application of IFRS 16 amounts to SEK 23.2 (16.0) million, this being included in its entirety under administration costs.

Adjusted EBIT amounted to SEK 91.8 million. Adjusted for acquisition and restructuring costs, adjusted EBIT amounted to SEK 122.4 (168.7) million, corresponding to a margin of 12 (19) percent.

EBITDA amounted to SEK 152.3 million. Adjusted for acquisition and restructuring costs, EBITDA amounted to SEK 182.9 (204.8) million, corresponding to a margin of 18 (23) percent.

Net financial items amounted to SEK 31.3 (13.8) million and consisted of interest income on bank balances of SEK 15.4 (23.6) million, interest costs on short-term loans of SEK -2.5 (-4.8) million, currency effects from a short-term loan in connection with the acquisition of Intelligent Ultrasound and the revaluation of intra-group loans of SEK 22.0 (-4.2) million, and the effect of IFRS 16 of SEK -3.7 (-0.8) million.

Net profit for 2025 amounted to SEK 66.8 (131.6) million. The tax expense for the year of SEK 33.3 (26.4) million consists of estimated tax on profit for the year and a change in deferred tax assets. This year's tax expense includes US taxes attributable to the previous year and taxes that are not linked to taxable income. Combined with the effect of the loss in Intelligent Ultrasound, this means that the effective tax rate increased. Profit includes acquisition costs of SEK 22.6 million for Intelligent Ultrasound, which are not tax deductible.

For 2025, there are tax-loss carry-forwards in the US attributable to Mimic Technologies, and in the UK attributable to Intelligent Ultrasound.

Cash flow

For 2025, cash flow from operating activities amounted to SEK 79.8 million, compared with SEK 137.2 million for 2024. Cash flow from changes in working capital amounted to SEK -61.7 (-65.9) million. Inventory has increased. Accounts receivable remain unchanged, while accrued income has increased. Short-term liabilities also increased.

Cash flow from investing activities amounted to SEK -134.3 (-47.5) million. SEK -84.9 million is attributable to the acquisition of Intelligent Ultrasound, see note 5 on pages 21 and 22. The remaining part consists mainly of investments in development related to the company's software. During the second part of the year, SEK 4.7 million was invested in the company's ongoing construction of new production facilities in Tel Aviv, which are expected to be commissioned in the second quarter of 2026.

Cash flow from financing activities amounted to SEK -259.7 (227.7) million, where SEK -24.3 (-2.2) million was attributable to changes in lease liabilities in accordance with IFRS 16. In connection with the offer to acquire Intelligent Ultrasound in December 2024, a short-term loan of GBP 17 million was taken out. This was repaid during the first quarter, which negatively impacted cash flow from financing activities by SEK 235.4 million.

Net cash flow for the year, including currency effects in liquid assets, was SEK -351.7 (333.8) million.

General comments on the accounts

Surgical Science's operations are structured into two business areas; Educational Products and Industry/OEM.

Sales within Educational Products consist of sales of the company's proprietary simulators (hardware and software) to the hospital market, as well as of service revenue related to the installed base of these simulators. The revenue from simulators is mainly of a one-off nature, while service revenue recurs throughout the term of each contract.

Sales within Industry/OEM consist in part of license revenue from the company's software, which is primarily attributable to the robotic surgery area. Revenue consists partly of revenue linked to each robot's serial number (fixed for each unit) and partly of recurring revenue linked to the installed base or use of the software, for example. Development revenue is also included, which is obtained when Surgical Science works to adapt the company's software to the customer's hardware platform. The area also includes the sale of simulators to OEM customers, primarily in the vascular area but also in ultrasound, for example, as well as service revenue related to the installed base of these simulators.

Pages 16 to 18 of Surgical Science's annual report for 2024 provides a detailed account of the company's business model and the various revenue streams. Pages 19 and 20 provide a general description of the customer journey with the robotics companies.

The gross margin is affected by the distribution of revenues, as the different revenue streams, "proprietary simulators containing hardware", "service revenues", "development revenues" and "license revenues", have different gross margins. A higher share of license revenue has a positive impact on the gross margin.

Surgical Science applies a functionally arranged income statement in which the gross margin also includes the salaries of employees working with production, quality control, and support, in addition to direct materials and spare parts. In addition, the salaries of development department employees working on development revenue-generating projects are included. Shared costs, such as premises and IT, are distributed in accordance with an allocation template for all the different functions.

Other operating income and operating costs consist predominantly of exchange rate fluctuations on operating assets and operating liabilities in foreign currencies.

As Surgical Science does not have any loan financing (except for a short-term loan of GBP 17 million between the fourth quarter of 2024 and the first quarter of 2025, related to the

acquisition of Intelligent Ultrasound), net financial items consist mainly of interest on bank balances, revaluation of internal loan receivables/payables to subsidiaries, and the impact of IFRS 16.

Loss carry-forwards remained in the US for 2024, attributable to Mimic Technologies. For 2025, there were tax-loss carry-forwards in the US attributable to Mimic Technologies, and in the UK attributable to Intelligent Ultrasound.

Impact of US tariffs

For 2025, Surgical Science's total sales (for both business areas) of simulators to the US were approximately SEK 220 million. These sales are directly affected by tariffs. With a 15 percent tariff level, Surgical Science estimates the impact to be around SEK 15 million per year. During the second half of 2025, these costs have been added to the price of the products.

Exposure to foreign currency

Surgical Science is mainly exposed to USD, ILS, EUR, and GBP. Exposure varies depending on how large a proportion of the revenues and costs are made up of these currencies in relation to the company's total revenues and costs. The company has not hedged its flows by way of hedging agreements.

In 2025, the USD weakened by 7 percent on average and by 16 percent on the closing date of December 31, which had a significant impact on Surgical Science's revenues and profit. Where possible, a transition has been made to invoicing customers in EUR instead of USD.

For the full year 2025, Surgical Science's revenues had the following approximate distribution across different currencies: USD 77 (79) percent, EUR 17 (14) percent, SEK 3 (2) percent, GBP 2 (4) percent, other (e.g. ILS) 1 (1) percent.

Costs for the full year 2025 had the following approximate distribution across different currencies: USD 26 (29) percent, ILS 43 (41) percent, SEK 20 (15) percent, GBP 7 (11) percent, other (e.g. EUR) 4 (4) percent.

Financial position

As at December 31, 2025, the group's cash and cash equivalents amounted to SEK 616.4 million, equity to SEK 4,273.1 million, and the equity/assets ratio was 91 percent. As at December 31, 2024, the group's cash and cash equivalents amounted to SEK 968.2 million, equity to SEK 4,828.6 million, and the equity/assets ratio was 88 percent. As at December 31, 2025, equity per share amounted to SEK 83.74 (94.63).

Parent company

The parent company, Surgical Science Sweden AB, holds shares in subsidiaries and the portion of Surgical Sciences' operations that are conducted in Sweden. Several group-wide functions are also organized within the parent company. Due to internal transactions between the various group companies, it is not possible to draw general conclusions from the parent company's figures regarding sales and operating costs.

In the first quarter, dividend of GBP 37 million was received from Intelligent Ultrasound, as the company was acquired with a large cash reserve. In the fourth quarter, shares in subsidiaries were impaired by SEK 569.2 million to reflect the lower equity in Intelligent Ultrasound as a result of this. Both items are included in the parent company's net financial items. The impairment has no effect on the group.

In the third quarter, USD 10 million was received in dividend from the US subsidiary Surgical Science North America. The amount is included in net financial items. During the fourth quarter, a merger took place between the parent company and the former subsidiary SenseGraphics AB. A consequence of this is that the previous group adjustment items relating to the acquisition of SenseGraphics – customer contracts and goodwill – are now included in the parent company's balance sheet.

Outlook

Surgical Science's strategy is to have two separate business areas. The focus of Educational Products is on customers in education and training, who use the company's proprietary simulators to increase patient safety through effective, generic training, the results of which can be measured objectively. Customers have validated the simulators over many years by way of clinical studies. The other business area, Industry/OEM, primarily makes use of Surgical Science's software resources, which enable medical device companies to integrate product-specific simulation into their clinical products. This makes it possible to generate a return on Surgical Science's development work, which has been ongoing for more than 25 years. The company perceives the strongest future growth to be in this area. In robotic surgery, the principal business model involves a development fee for customization/integration with the customer's products and then a software license for each unit or based on the installed base or on usage. Surgical Science retains full copyright over its product.

Underlying growth in the market for medical simulation is favorable. The largest market for medical simulation is the US, followed by Europe and Asia. Over the next few years, growth is expected to be strongest in countries where driving forces include economic development, an increased focus on patient safety, and a large population, such as China and India. The

market for robot-assisted surgery is expected to grow quicker than other parts of the market.

The overall objectives for Surgical Science 2025 have been to:

- Ensure successful integration of Intelligent Ultrasound and safeguard planned synergies.
- Establish broader partnerships and increase the number of customers in the Medical Device Simulation segment of Industry/OEM.
- Grow organic sales in Educational Products by 10 to 15 percent.
- Continue to expand the product portfolio through further product launches.
- Improve gross margin in Educational Products, including Intelligent Ultrasound, by streamlining the product portfolio and increasing average selling price.
- Ensure a high level of employee commitment by continuing to build and maintain the culture and the company's core values.
- Improve internal efficiency and the level of automation to respond more quickly and cost-effectively to increased customer demand and to handle more customers and business.
- Be prepared to make further acquisitions when the time is right.

Surgical Science has an organization where a sizable portion of its employees are global leaders in software development for medical simulation. This gives the company the capacity to work with the development of the core technology for future simulation, with on-time delivery of adaptations of simulation software to customers in Industry/OEM, and to continue to launch new applications for its proprietary products within Educational Products. To remain the world leader in realistic real-time simulations of medical procedures, improving the core technology is critical, and Surgical Science is continuing to invest in this area.

The company in brief

Operations

Surgical Science was founded in 1999 and works with simulation technologies. The foundation of the company is its proprietary software and hardware for simulating interactions between instruments and anatomy. Based on its proprietary technology, Surgical Science develops and sells turnkey simulation systems used to train surgeons and other medical specialists. The operations are conducted within the framework of the Educational Products business area. Surgical Science also works with simulation solutions for medical device companies that develop surgical instruments for clinical applications (such as robot-assisted surgery) – this work is conducted within the Industry/OEM business area.

Purpose and vision

Surgical Science's purpose is to empower all healthcare professionals to reach their full potential in order to improve healthcare outcomes and save lives. The company's vision is a world where all medical professionals have been trained and objectively certified in a safe and lifelike simulated environment.

Financial targets

On December 8, 2025, Surgical Science announced new financial targets. Growth shall amount to 10-15 percent annually with an adjusted EBIT of at least 15 percent. Profitability and some sales growth is expected for 2026, although not in line with the targets. The targets are expected to be met in 2027.

The targets are based on organic growth. Acquisitions will continue to be an important part of Surgical Science's strategy going forward and, in addition to this plan, may contribute to further growth.

Change of listing

In connection with the announcement of the new financial targets on December 8, 2025, the intention to begin the process of switching to the Nasdaq Main Market was also announced.

Strategy

The Educational Products business area has a broad global presence in hospitals and universities, while the Industry/OEM business area is based on close collaboration with medical device companies. Together, they create a scalable business model with recurring revenue streams and high customer loyalty, based on the company's goal of improving healthcare outcomes through medical simulation.

By establishing leading positions in two main business areas – Educational Products and Industry/OEM – Surgical Science ensures a balanced and synergy-driven platform for growth. Within each area, the company focuses on a number of simulation areas that are important for future growth, including minimally invasive surgery, ultrasound, emergency medicine, robotic surgery, and medical device simulation.

The demand for medical simulation is driven by several interacting factors: aging populations and an increased number of medical procedures, increased complexity in healthcare as a result of minimally invasive and robot-assisted surgery becoming more common, as well as a shortage of healthcare personnel and limited opportunities for traditional clinical training. At the same time, requirements in respect of quality, patient safety, and verified training are becoming more stringent, which – in combination with digitalization and VR – makes simulation an effective and scalable method for training and certifying healthcare personnel.

Other information

Organization and personnel

At the end of the year, there were 313 (274) employees, of whom 87 (75) were women and 226 (199) were men. Of these, 68 (64) were employed in Sweden, 152 (138) in Israel, 44 (54) in the US, 28 (1) in the UK, and the remaining 21 (17) mainly in Germany and China.

Information on transactions with related parties

In addition to his board fees, board member Thomas Eklund received consultancy fees of SEK 248 thousand in the second quarter for his work on the company's strategies during 2025.

No other transactions, materially impacting the company's profit or financial position were conducted with related parties during the quarter or year.

Proposed appropriation of profits

The board of directors intends to propose to the annual general meeting that no dividend be paid for 2025, that is SEK 0.00 per share.

Risk management

Surgical Science works on an ongoing basis to identify, assess and manage risks in various systems and processes. Risk analyses of day-to-day operations are performed on an ongoing basis and in connection with major activities.

The most significant strategic and operational risks affecting Surgical Science's operations and industry are described on pages 67 and 68 of the company's 2024 annual report. The principal risks and uncertainties include IP, market risks, competitors and technological development, industrial partnerships, employees, acquisitions and access to capital. To all intents and purposes, the risks reported by the company and outlined in the annual report, are judged to have remained unchanged.

Seasonal effects

Surgical Science's sales within the Educational Products business area can fluctuate between quarters, with the fourth quarter of the year having usually been the strongest. This is because many major hospitals use the calendar year as their budget year and hold off on purchases until they can see what funds remain in the budget toward the end of the year. In recent years, this effect has not been significant. In the US, this effect is not found to the same extent as in countries that are more heavily reliant on public funding.

In the Industry/OEM business area, there is no significant seasonal effect, as clinical products such as those used in robotic surgery, are less influenced by whether there is any budget remaining at the end of the year.

Annual general meeting and annual report

The annual general meeting of Surgical Science Sweden AB (publ) will be held on May 21, 2026. Shareholders wishing to have a matter considered by the meeting may request this in writing from the board. Such requests for matters to be addressed shall be submitted to Surgical Science Sweden AB (publ), Att: Chair of the board, Drakegatan 7A, SE-412 50 Gothenburg, Sweden and must be received by the board no later than seven weeks prior to the meeting and, in all instances, sufficiently early that the matter, if necessary, can be included in the notice convening the meeting.

Surgical Science's 2025 annual report is expected to be available for download from Surgical Science's website during the week of April 20 to 24.

Events after the balance sheet date

There have been no significant events to report following the end of the year.

Assurance

The board and CEO provide their assurance that this year-end report provides a fair overview of the company's operations, position and profit, and describes any significant risks and uncertainties that the company might face.

Gothenburg, February 19, 2026

Board of directors

This report has not been subject to review by the company's auditors.

Financial reports:

Interim reports and other financial reports are available at www.surgicalscience.com.

The following reports are planned for release:

Interim report January–March 2026: Wednesday, May 20

Interim report January–June 2026: Wednesday, August 19

Interim report January–September 2026: Thursday, November 12

Year-end report 2026: Tuesday, February 23, 2027

Other dates

Annual general meeting 2026: Thursday, May 21

Stock market and Certified Adviser:

Shares in Surgical Science Sweden AB (publ) have been traded on Nasdaq First North Growth Market since June 19, 2017. The company's Certified Adviser is DNB Carnegie Investment Bank AB.

Please address any questions to:

Tom Englund, CEO

Phone: +46 (0)70 916 16 81

tom.englund@surgicalscience.com

Anna Ahlberg, CFO

Phone: +46 (0)70 855 38 35

anna.ahlberg@surgicalscience.com

This is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons above on February 19, 2026, at 07:30 (CET).

This is a translation of the Swedish version of the year-end report. When in doubt, the Swedish wording prevails.

Condensed consolidated income statements

SEK thousands	January – December		October – December	
	2025	2024	2025	2024
Net sales	992,344	884,087	268,854	251,549
Cost of goods sold	-334,668	-286,189	-90,601	-81,474
Gross profit	657,676	597,897	178,253	170,076
Sales costs	-214,352	-175,260	-46,981	-49,898
Administration costs	-112,246	-77,119	-24,517	-22,338
Research and development costs	-222,109	-196,110	-59,753	-51,656
Other operating income and costs	-40,086	-5,087	-6,860	-7,056
Operating profit	68,883	144,320	40,142	39,128
Financial income and costs	31,255	13,773	2,353	295
Profit after financial items	100,137	158,093	42,495	39,423
Taxes	-33,319	-26,446	-9,240	-3,159
Net profit	66,818	131,646	33,255	36,264
Attributable to				
Parent company shareholders	66,818	131,646	33,255	36,264
Earnings per share, SEK	1.31	2.58	0.65	0.71
Earnings per share, SEK*	1.31	2.58	0.65	0.71
Amortization of intangible assets	-45,927	-36,892	-11,880	-9,296
Depreciation of tangible assets	-37,444	-23,623	-12,069	-7,030

* After dilution. See Note 4 for information regarding warrants programs.

Consolidated statement of income and other comprehensive income

SEK thousands	January – December		October – December	
	2025	2024	2025	2024
Net profit	66,818	131,646	33,255	36,264
Other comprehensive income				
<i>Items that have been or can be reclassified to net profit</i>				
Translation differences on translation of foreign operations	-629,888	344,546	-59,897	341,692
Total other comprehensive income	-629,888	344,546	-59,897	341,692
Comprehensive income	-563,070	476,192	-26,642	377,956
Comprehensive income attributable to				
Parent company shareholders	-563,070	476,192	-26,642	377,956

Condensed consolidated statement of financial position

SEK thousands	Dec 31, 2025	Dec 31, 2024
ASSETS		
Non-current assets		
Capitalized expenditure for product development	116,784	98,457
Patents, trademarks, and concessions	51,150	61,759
Customer contracts	70,734	92,445
Technology	40,483	57,055
Goodwill	3,077,234	3,615,848
Other intangible fixed assets	21,750	2,189
Tangible fixed assets	106,346	101,534
Deferred tax assets	13,581	16,331
Other financial fixed assets	8,618	8,049
Total non-current assets	3,506,680	4,053,666
Current assets		
Inventories	205,974	179,583
Accounts receivable	136,976	136,702
Other current receivables	71,271	43,652
Prepaid expenses and accrued income	154,040	97,914
Cash and cash equivalents	616,425	968,155
Total current assets	1,184,686	1,426,007
TOTAL ASSETS	4,691,366	5,479,673
EQUITY AND LIABILITIES		
Equity attributable to parent company shareholders	4,273,054	4,828,639
Non-current liabilities	125,549	138,313
Liabilities to credit institutions	1,625	235,408
Other current liabilities	291,138	277,314
Total liabilities	418,312	651,035
TOTAL EQUITY AND LIABILITIES	4,691,366	5,479,673

Consolidated changes in equity

SEK thousands	Attributable to parent company shareholders				Total equity
	Share capital	Other capital contributions	Provisions	Profit and loss carried forward, incl. profit for the period	
Opening balance January 1, 2024	2,551	3,398,121	436,777	507,763	4,345,212
Profit for the year				131,646	131,646
Other comprehensive income for the year			344,546		344,546
Warrants program IFRS 2			7,235		7,235
Closing balance December 31, 2024	2,551	3,398,121	788,557	639,409	4,828,639
Opening balance January 1, 2025	2,551	3,398,121	788,557	639,409	4,828,639
Profit for the year				66,818	66,818
Other comprehensive income for the year			-629,888		-629,889
Warrants program IFRS 2			7,486		7,486
Closing balance December 31, 2025	2,551	3,398,121	166,155	706,227	4,273,054

Condensed consolidated cash flow statements

SEK thousands	January – December		October – December	
	2025	2024	2025	2024
Operating activities				
Profit before financial items	68,883	144,320	40,142	39,128
Adjustment for non-cash items, etc.	112,886	67,711	32,000	23,853
Interest paid/received	9,226	18,768	1,776	7,071
Tax paid	-49,500	-27,686	1,993	-11,177
Cash flow from operating activities before changes in working capital	141,494	203,113	75,910	58,875
Changes in working capital				
Increase (-)/Decrease (+) in inventories	-16,392	-11,556	-728	12,066
Increase (-)/Decrease (+) in operating receivables	-87,612	-20,238	-36,116	25,626
Increase (+)/Decrease (-) in operating liabilities	42,306	-34,094	33,819	-39,899
Cash flow from changes in working capital	-61,699	-65,888	-3,025	-2,206
Cash flow from operating activities	79,795	137,225	72,886	56,668
Investing activities				
Investments in tangible fixed assets	-11,678	-6,104	-6,237	-469
Investments in intangible fixed assets	-37,660	-41,426	-8,886	-11,658
Investment in business	-84,914	-	-	-
Cash flow from investing activities	-134,251	-47,530	-15,122	-12,126
Financing activities				
Change in non-current liabilities	48	-5,525	1,872	488
Change in liabilities to credit institutions	-235,407	235,408	-	235,408
Change in lease liabilities	-24,316	-2,230	-27,532	4,145
Cash flow from financing activities	-259,675	227,653	-25,660	240,041
Cash flow for the period	-314,131	317,348	32,104	284,582
Opening cash and cash equivalents	968,155	634,366	597,387	666,324
Exchange-rate difference in cash and cash equivalents	-37,599	16,441	-13,066	17,249
Closing cash and cash equivalents	616,425	968,155	616,425	968,155

Key figures, group

	January – December		October – December	
	2025	2024	2025	2024
Net sales growth, %	12.2	0.1	6.9	10.7
Gross margin, %	66.3	67.6	66.3	67.6
EBITDA margin, %	15.3	23.2	23.8	22.0
Operating margin, %	6.9	16.3	14.9	15.6
Profit margin, %	6.7	14.9	12.4	14.4
Equity/assets ratio, %	91.1	88.1	91.1	88.1
Shares outstanding at end of period	51,026,236	51,026,236	51,026,236	51,026,236
Shares outstanding at end of period*	51,026,236	51,026,236	51,026,236	51,026,236
Average shares outstanding	51,026,236	51,026,236	51,026,236	51,026,236
Average shares outstanding*	51,026,236	51,026,236	51,026,236	51,026,236
Equity per share, SEK	83.74	94.63	83.74	94.63
Equity per share, SEK*	83.74	94.63	83.74	94.63
Dividend per share, SEK	0.00	0.00	0.00	0.00
Share price on the balance sheet date, SEK	32.50	155.90	32.50	155.90
Average number of employees	309	256	310	259

* After dilution. See Note 4 for information regarding warrants programs. | See page 23 for definitions of key figures.

Consolidated income statements by quarter

SEK thousands	Oct–Dec 2025	Jul–Sep 2025	Apr–Jun 2025	Jan–Mar 2025	Oct–Dec 2024	Jul–Sep 2024	Apr–Jun 2024	Jan–Mar 2024
Net sales	268,854	263,641	209,157	250,691	251,549	231,828	212,466	188,243
Cost of goods sold	-90,601	-93,211	-72,763	-78,092	-81,474	-70,816	-68,982	-64,918
Gross profit	178,253	170,430	136,394	172,599	170,076	161,012	143,484	123,325
Sales costs	-46,981	-56,466	-57,783	-53,122	-49,898	-42,617	-42,290	-40,456
Administration costs	-24,517	-20,484	-23,493	-43,752	-22,338	-18,040	-20,998	-15,744
Research and development costs	-59,753	-55,027	-52,123	-55,206	-51,656	-50,575	-48,841	-45,039
Other operating income and costs	-6,860	-11,204	-25,440	3,419	-7,056	-3,995	2,075	3,890
Operating profit	40,142	27,249	-22,446	23,938	39,128	45,786	33,430	25,976
Financial income and costs	2,353	2,900	3,728	22,273	295	7,239	4,376	1,862
Profit after financial items	42,495	30,148	-18,718	46,211	39,423	53,025	37,806	27,838
Taxes	-9,240	-9,746	-1,359	-12,974	-3,159	-10,002	-9,238	-4,046
Net profit	33,255	20,402	-20,077	33,237	36,264	43,023	28,568	23,792
Attributable to								
Parent company shareholders	33,255	20,402	-20,077	33,237	36,264	43,023	28,568	23,792
Earnings per share, SEK	0.65	0.40	-0.39	0.65	0.71	0.84	0.56	0.47
Earnings per share, SEK*	0.65	0.40	-0.39	0.65	0.71	0.84	0.56	0.47
Average shares outstanding	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236
Average shares outstanding*	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236
Shares outstanding at end of period	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236
Shares outstanding at end of period*	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236	51,026,236

* After dilution. See Note 4 for information regarding warrants programs.

Parent company income statements

SEK thousands	January – December		October – December	
	2025	2024	2025	2024
Net sales	381,109	126,574	146,155	44,103
Cost of goods sold	-185,285	-55,459	-76,701	-23,167
Gross profit	195,824	71,115	69,454	20,936
Sales costs	-28,388	-18,915	-12,418	-6,247
Administration costs	-48,578	-21,441	-31,620	-6,972
Research and development costs	-30,704	-28,960	-11,735	-7,943
Other operating income and costs	-15,609	-5,257	-3,879	-591
Operating profit	72,546	-3,457	9,802	-817
Other financial income and costs	42,900	7,800	-565,962	-4,495
Profit after financial items	115,446	4,343	-556,161	-5,312
Appropriations (group contributions)	-2	63,557	-2	63,557
Taxes	-26,529	-14,437	-8,218	-12,448
Net profit	88,914	53,464	-564,381	45,797
Amortization of intangible assets	-40,899	-7,978	-33,439	-1,972
Depreciation of tangible assets	-783	-957	-207	-219

Because the parent company has no items to report under Other comprehensive income, no statement of comprehensive income has been prepared.

Condensed parent company balance sheets

SEK thousands	Dec 31, 2025	Dec 31, 2024
ASSETS		
Non-current assets		
Capitalized expenditure for product development	29,916	30,664
Customer contracts	15,337	–
Goodwill	89,405	–
Other intangible fixed assets	1,396	1,075
Tangible fixed assets	976	1,687
Participations in group companies	2,870,253	3,131,505
Total non-current assets	3,007,284	3,164,931
Current assets		
Inventories	16,090	6,659
Accounts receivable	24,868	27,761
Current receivables from group companies	47,524	71,845
Other current receivables	15,988	1,940
Prepaid expenses and accrued income	89,919	14,089
Cash and bank position	548,076	659,075
Total current assets	742,465	781,370
TOTAL ASSETS	3,749,749	3,946,300
EQUITY AND LIABILITIES		
Equity	3,528,364	3,567,762
Liabilities to credit institutions	1,625	235,408
Current receivables from group companies	115,823	78,112
Other current liabilities	100,778	65,019
Total liabilities	218,226	378,539
TOTAL EQUITY AND LIABILITIES	3,749,749	3,946,300

Note 1. Accounting principles

As regards the group, this interim report has been prepared in accordance with the Annual Accounts Act and IAS 34 Interim Financial Reporting and, as regards the parent company, in accordance with the Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities. Unless stated otherwise below, the accounting principles applied for the group and the parent company are the same as those applied in preparing the most recent annual report.

Disclosures in accordance with IAS 34.16A appear not only in the financial statements and the accompanying notes, but also in other parts of the interim report.

Note 2. Group operating segments

Revenue by business area and revenue stream

SEK thousands	January – December		October – December	
	2025	2024	2025	2024
Educational Products	501,542	442,496	129,546	125,044
- Simulators, hardware and software	423,986	364,345	109,823	107,092
- Service and support revenue	77,557	78,151	19,723	17,952
Industry/OEM	490,802	441,591	139,308	126,505
- Simulators, hardware and software	100,479	126,716	21,395	42,506
- Service and support revenue	13,508	12,095	4,088	2,968
- License revenue	300,576	271,657	92,297	76,363
- Development revenue	76,239	31,123	21,528	4,668
Net sales	992,344	884,087	268,854	251,549

Revenue by business area and geographic area

SEK thousands	January – December		October – December	
	2025	2024	2025	2024
Educational Products	501,542	442,496	129,546	125,044
- Europe	136,547	92,900	35,362	33,981
- North and South America	245,934	207,011	60,921	42,718
- Asia	97,439	111,149	30,484	38,497
- Other	21,622	31,436	2,779	9,848
Industry/OEM	490,802	441,591	139,308	126,505
- Europe	49,151	59,893	8,509	26,380
- North and South America	390,931	355,988	119,566	96,436
- Asia	44,674	21,140	10,950	2,866
- Other	6,046	4,570	283	823
Net sales	992,344	884,087	268,854	251,549

Revenue by product group

SEK thousands	January – December		October – December	
	2025	2024	2025	2024
Robotics	382,925	336,593	124,021	98,547
Vascular surgery	135,864	153,946	27,808	43,667
Laparoscopy	92,322	124,494	22,459	42,042
Endoscopy	110,281	112,345	31,972	25,813
Ultrasound	163,403	89,201	39,808	26,963
Other	107,546	67,507	22,785	14,517
Net sales	992,344	884,087	268,854	251,549

Note 3. Financial instruments

SEK thousands	Dec 31, 2025	Dec 31, 2024
Financial assets	771,252	1,119,923
Financial liabilities	224,655	445,069

The group's financial assets and liabilities are valued at amortized cost, with the exception of the deferred contingent consideration recognized as a liability and measured at fair value. The carrying amount is considered to be a reasonable approximation of the fair value of the group's assets and liabilities in the balance sheet.

Note 4. Warrants programs

Warrants 2022_25

Surgical Science's annual general meeting on May 12, 2022 resolved to establish an incentive program for company employees. Each warrant entitled the holder to subscribe for one share in the company for SEK 175.70 during the period June 10 to July 10, 2025. The company subsidized the warrants program so that participants received warrants as a benefit. Participants were required to pay tax on this benefit, with the premium being calculated at SEK 28.74 per warrant.

During the subscription period, the company's average share price was below the set exercise price, which meant that no options were exercised. All 200,000 warrants thus expired without value. As a result, both the number of shares and the share capital remained unchanged, and there was no dilution of existing shareholders' ownership interests or voting rights.

Incentive program costs

For 2025, the program has impacted profits negatively by SEK 0.7 million (1.4). The amount comprises the IFRS 2 cost attributable to Israel and the US and was distributed across the term of the program until July 2025. Cumulatively, the program has impacted profits negatively by SEK 5.6 million.

Warrants 2023_26

Surgical Science's annual general meeting on May 17, 2023 resolved to establish an incentive program for company employees. Each warrant entitles the holder to subscribe for one share in the company for SEK 294.70 during the period June 15 to July 15, 2026. The company subsidizes the warrants program so that participants receive warrants as a benefit. Participants are required to pay tax on this benefit, with the premium being calculated at SEK 36.43 per warrant.

During the current period, the average share price for the period, the closing price on the balance sheet date, and the average share price for the rolling 12-month period were all below the exercise price for the warrant program, whereby the program did not entail any dilution effect. Fully exercised, the incentive program will increase Surgical Science's share capital by SEK 13,000 and the number of shares by 260,000, corresponding to the dilution of the total number of shares and votes by about 0.5 percent.

Incentive program costs

For 2025, the program has impacted profits negatively by SEK 1.0 (2.5) million. The amount comprises the IFRS 2 cost attributable to Israel and the US and is distributed across the term of the program until July 2026. Cumulatively, the program has impacted profits negatively by SEK 6.7 million.

Warrants 2024_27

Surgical Science's annual general meeting on May 16, 2024 resolved to establish two incentive programs for company employees. Each warrant entitles the holder to subscribe for one share in the company for SEK 170.50 during the period June 14 to July 14, 2027. The company subsidizes the warrants programs so that participants receive warrants as a benefit. Participants are required to pay tax on this benefit, with the premium being calculated at SEK 33.31 per warrant.

During the current period, the average share price for the period, the closing price on the balance sheet date, and the average share price for the rolling 12-month period were all below the exercise price for the warrant program, whereby the program did not entail any dilution effect. Fully exercised, the two incentive programs will increase Surgical Science's share capital by SEK 16,400 and the number of shares by 328,000, corresponding to the dilution of the total number of shares and votes by about 0.6 percent.

Incentive program costs

For 2025, the program has impacted profits negatively by SEK 1.7 (4.0) million. The amount comprises the IFRS 2 cost attributable to Israel and the US and is distributed across the term of the program until July 2027. Cumulatively, the program has impacted profits negatively by SEK 5.7 million.

Warrants 2025_28

Surgical Science's annual general meeting on May 15, 2025 resolved to establish two incentive programs for company employees. Each warrant entitles the holder to subscribe for one share in the company for SEK 173.90 during the period June 14 to July 14, 2028. The company subsidizes the warrants programs so that participants receive warrants as a benefit. Participants are required to pay tax on this benefit, with the premium being calculated at SEK 36.42 per warrant.

Fully exercised, the two incentive programs will increase Surgical Science's share capital by SEK 20,100 and the number of shares by 402,000, corresponding to the dilution of the total number of shares and votes by about 0.8 percent. As at the balance sheet date of December 31, 2025, the warrants programs entailed no dilution.

Incentive program costs

For 2025, the programs have impacted profits negatively by SEK 4.9 (-) million, of which SEK 0.8 million pertains to social security contributions on the Swedish participants' premiums, which were provided free of charge. The remainder of the cost, SEK 4.1 million, is attributable to the calculation of IFRS 2. The amount comprises the entire IFRS 2 cost for the Swedish portion of the programs, the remainder is attributable to Israel, the US, and the UK and is distributed across the term of the programs until July 2028.

Programs 2023_26, 2024_27, and 2025_28

The board is authorized to adjust the program in response to organizational changes and to specific rules or market conditions in other countries. Most of the company's employees are employed outside Sweden, in the US and in Israel. For tax reasons, these employees are contractually entitled to subscribe for shares (Non-Qualified Stock Options) rather than warrants. In accordance with generally accepted practices in these markets, participants receive these shares free of charge.

Note 5. Acquisition of business

On December 19, 2024, Surgical Science announced a recommended offer to acquire 100 percent of the issued share capital of Intelligent Ultrasound Group plc (IU), a UK-based ultrasound simulation company listed on the Alternative Investment Market of the London Stock Exchange. The acquisition, which was completed on February 18, 2025, amounted to approximately SEK 630 million on a fully diluted basis, corresponding to a value of approximately SEK 65 million on a cash and debt-free basis. The valuation implies a sales multiple (2023) of approximately 0.5 times Intelligent Ultrasound's sales.

Rationale for the acquisition

- Strategic portfolio enhancement: Intelligent Ultrasound offers proprietary ultrasound simulation solutions for several medical fields that complement Surgical Science's offering in this area.
- Innovation-led expansion: Intelligent Ultrasound will become part of Surgical Science's development organization, providing volumetric ultrasound technology.
- Larger commercial footprint in the UK and US: Direct sales are established in the UK market, while the commercial footprint in the US is expanded.

- Economies of scale: With increased scale, Surgical Science can generate greater customer value by effectively leveraging shared functions and sales channels.
- Attractive price: Following the sale of its AI business to GE Healthcare, Surgical Science is acquiring Intelligent Ultrasound at a sales multiple of approximately 0.5, more than doubling the company's sales in ultrasound in 2024.

The purchase consideration, the fair value of the acquired net assets and goodwill are as follows:

SEK thousand	
Cash payment	610,449
Fair value of acquired net assets	-593,857
Total goodwill	16,592

Goodwill is attributable to the acquired workforce and synergies in the form of cost savings that do not meet the criteria for separate recognition.

The purchase consideration amounted to GBP 45.2 million/SEK 610 million after full dilution on a cash and debt-free basis. There is no conditional purchase consideration.

The assets and liabilities recognized as a result of the acquisition are shown below:

Carrying amount of identifiable assets and liabilities at the time of acquisition

SEK thousand	Recognized value in Intelligent Ultrasound as at February 18, 2025	Fair value adjustment	Fair value reported in the group
Intangible fixed assets	27,898		27,898
Tangible fixed assets	11,285		11,285
Non-current receivables	820		820
Inventories	22,399		22,399
Current receivables	24,122		24,122
Prepaid expenses and accrued income	40,412		40,412
Cash and cash equivalents	525,535		525,535
Non-interest-bearing liabilities	-9,030		-9,030
Accounts payable	-13,312		-13,312
Other current liabilities	-27,214		-27,214
Prepaid income and accrued expenses	-9,058		-9,058
Net identifiable assets and liabilities	593,857		593,857

Acquisition costs

Acquisition-related costs of SEK 22.6 million are included in the group's administration costs in the income statement and in operating activities in the cash flow statement.

In the parent company, these costs have been reported as an increase in shares in subsidiaries.

Financing

The acquisition was financed with the company's own funds. A short-term loan of GBP 17 million (SEK 235.4 million as at December 31, 2024) was taken out in connection with the acquisition, which was repaid during the first quarter of 2025. In connection with this, dividend of GBP 37 million has been paid from IU to the parent company Surgical Science Sweden AB.

Revenue and contributions after the acquisition

For the period February 18 to December 31, IU contributed revenue of SEK 75.3 million and a net result of SEK -18.7 million to the group. The result includes restructuring costs of SEK 5.3 million.

Had the acquisition taken place on January 1, 2025, management estimates that the contribution to the group's revenue for 2025 would have amounted

to SEK 80.2 million and the contribution to the group's result after tax for the same period would have amounted to SEK -33.1 million (excluding acquisition-related costs of GBP 1.2 million or SEK 16.4 million recognized in the period prior to the acquisition of IU).

Efficiency improvements

At the time of the acquisition, Surgical Science estimated that the efficiency gains that could be achieved would result in annual cost savings of between GBP 1.5 and 2.0 million (then corresponding to between SEK 20.3 and 27.0 million). Intelligent Ultrasound had sales of GBP 8.6 million in 2024 with an operating profit of GBP -2.7 million. The number of employees was 48. To date, annual cost savings of approximately GBP 2.5 million have been achieved relative to the cost structure that existed in the company at the time of acquisition. The savings primarily stem from lower costs related to the company's previous IPO and staffing reductions, mainly in the sales organization. These cost savings began to take effect during the second quarter. Restructuring costs of SEK 3.9 million (GBP 0.3 million) were recognized in the first quarter. During the third quarter, an additional SEK 1.5 million (GBP 0.1 million) was spent, bringing the total restructuring costs for the year to SEK 5.3 million (GBP 0.4 million).

For further information, please refer to press releases and the annual report for 2024.

Note 6. Goodwill

Reconciliation of goodwill in the group

SEK thousand	Jan 1, 2025 - Dec 31, 2025	Jan 1, 2024 - Dec 31, 2024
Opening acquisition value	3,615,848	3,328,683
Acquisitions for the year	16,564	-
Revaluation at the balance sheet date	-555,178	287,165
Closing accumulated cost	3,077,234	3,615,848
Closing carrying amount	3,077,234	3,615,848

Definitions of key figures

Surgical Science believes that the key figures reported facilitate an understanding of the company's financial trends.

EBITDA margin

Operating profit less depreciation, amortization, and impairment of tangible and intangible assets as a percentage of net sales. Over time, this key figure conveys a deeper understanding of the company's profitability.

Equity per share

Reported equity divided by the number of shares outstanding at the end of the period. The key figure gives an idea of how much capital per share is attributable to shareholders.

Average number of shares

The weighted average number of shares outstanding during the period.

Average number of shares after dilution

The weighted average number of shares outstanding during the period, adjusted for any dilution effect from warrants.

Adjusted EBIT margin

Operating profit less depreciation, amortization, and impairment of surplus values related to acquisitions as a percentage of net sales. Over time, this key figure conveys a deeper understanding of the company's profitability.

Average number of employees

The number of employees recalculated as full-time positions per month divided by the number of months in the period.

Net sales growth, %

Percentage change in net sales between two periods. This key figure conveys a view of the sales trend between periods.

Earnings per share

Profit for the period in relation to the weighted average of the number of shares during the period.

Earnings per share after dilution

Earnings after tax per share adjusted for any dilution effect from warrants.

Operating profit

Profit before financial items and tax. This key figure shows the operating profit regardless of the financing structure and tax rate.

Operating margin

Operating profit as a percentage of net sales. Over time, this key figure conveys a deeper understanding of the company's profitability.

Equity/assets ratio

Equity as a percentage of total assets. This key figure conveys a view of the extent to which the total assets have been financed by the owners.

Dividend per share

Dividend for the year divided by the number of shares outstanding on the date of payment of the dividend. Provides a picture of the value per share transferred to shareholders.

Profit margin

Profit for the year as a percentage of net sales. Over time, this key figure conveys a deeper understanding of the company's profitability.

surgicalscience

Head office

Surgical Science Sweden AB (publ)
Drakegatan 7A
SE-412 50 Gothenburg
Sweden
Phone: +46 31 741 65 60
E-mail: info@surgicalscience.com

Other offices in Sweden

Borgarfjordsgatan 6B
SE-164 55 Kista
Sweden
Phone: +46 31 741 65 60

Israel

3 Golan Street
Airport City, 7019900
Israel
Phone: +972 3 911 44 44

USA

23500 Mercantile, Suite F
Beachwood, Ohio 44122
USA
Phone: +1 800 918 1670

United Kingdom

Hodge House
114-116 St Mary Street
Cardiff, CF10 1DY
United Kingdom
Phone: +44 29 2075 6534

Sales office, China

906, Excellence Century Center
Tower 3
2030 Jintian Road, Futian District,
Shenzhen
China 518026
Phone: +86 755 23985994